AELIS FARMA SAS (AELIS.PA) Fundamental Analysis & Valuation

EPA:AELIS • FR0014007ZB4

Current stock price

1.23 EUR
-0.05 (-4.06%)
Last:

This AELIS.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. AELIS.PA Profitability Analysis

1.1 Basic Checks

  • In the past year AELIS has reported negative net income.
  • In the past year AELIS has reported a negative cash flow from operations.
  • AELIS had negative earnings in 4 of the past 5 years.
  • AELIS had negative operating cash flow in 4 of the past 5 years.
AELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFAELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

1.2 Ratios

  • AELIS has a Return On Assets of -52.61%. This is in the lower half of the industry: AELIS underperforms 65.43% of its industry peers.
  • AELIS's Return On Equity of -134.05% is in line compared to the rest of the industry. AELIS outperforms 44.44% of its industry peers.
Industry RankSector Rank
ROA -52.61%
ROE -134.05%
ROIC N/A
ROA(3y)-31.08%
ROA(5y)-24.2%
ROE(3y)-61.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AELIS.PA Yearly ROA, ROE, ROICAELIS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AELIS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AELIS.PA Yearly Profit, Operating, Gross MarginsAELIS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. AELIS.PA Health Analysis

2.1 Basic Checks

  • AELIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • AELIS has more shares outstanding than it did 1 year ago.
  • AELIS has more shares outstanding than it did 5 years ago.
  • AELIS has a worse debt/assets ratio than last year.
AELIS.PA Yearly Shares OutstandingAELIS.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
AELIS.PA Yearly Total Debt VS Total AssetsAELIS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • AELIS has a Debt/Equity ratio of 0.74. This is a neutral value indicating AELIS is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.74, AELIS perfoms like the industry average, outperforming 48.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC7.28%
AELIS.PA Yearly LT Debt VS Equity VS FCFAELIS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • AELIS has a Current Ratio of 3.18. This indicates that AELIS is financially healthy and has no problem in meeting its short term obligations.
  • AELIS has a better Current ratio (3.18) than 64.20% of its industry peers.
  • AELIS has a Quick Ratio of 3.18. This indicates that AELIS is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 3.18, AELIS is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.18
Quick Ratio 3.18
AELIS.PA Yearly Current Assets VS Current LiabilitesAELIS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AELIS.PA Growth Analysis

3.1 Past

  • The earnings per share for AELIS have decreased strongly by -13.00% in the last year.
  • AELIS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -94.09%.
  • AELIS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -33.42% yearly.
EPS 1Y (TTM)-13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.8%
Revenue 1Y (TTM)-94.09%
Revenue growth 3Y-33.42%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • AELIS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 146.58% yearly.
  • AELIS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 88.24% yearly.
EPS Next Y-131.58%
EPS Next 2Y70.14%
EPS Next 3Y146.58%
EPS Next 5YN/A
Revenue Next Year-52.86%
Revenue Next 2Y33.1%
Revenue Next 3Y88.24%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AELIS.PA Yearly Revenue VS EstimatesAELIS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
AELIS.PA Yearly EPS VS EstimatesAELIS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 1 2

More info and screens

Find the best growth stocksShow best growing peers

3

4. AELIS.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AELIS. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 7.02, the valuation of AELIS can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, AELIS is valued cheaply inside the industry as 98.77% of the companies are valued more expensively.
  • AELIS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.62.
Industry RankSector Rank
PE N/A
Fwd PE 7.02
AELIS.PA Price Earnings VS Forward Price EarningsAELIS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AELIS.PA Per share dataAELIS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AELIS's earnings are expected to grow with 146.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.14%
EPS Next 3Y146.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AELIS.PA Dividend Analysis

5.1 Amount

  • No dividends for AELIS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AELIS.PA Fundamentals: All Metrics, Ratios and Statistics

AELIS FARMA SAS

EPA:AELIS (4/23/2026, 7:00:00 PM)

1.23

-0.05 (-4.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners28.04%
Inst Owner ChangeN/A
Ins Owners17.74%
Ins Owner ChangeN/A
Market Cap16.86M
Revenue(TTM)446.00K
Net Income(TTM)-8.20M
Analysts84.44
Price Target11.22 (812.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.02
P/S 37.81
P/FCF N/A
P/OCF N/A
P/B 2.76
P/tB 2.85
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)0.18
Fwd EY14.24%
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.03
BVpS0.45
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -52.61%
ROE -134.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.08%
ROA(5y)-24.2%
ROE(3y)-61.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.44%
Cap/Sales 6.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.18
Quick Ratio 3.18
Altman-Z N/A
F-Score2
WACC7.28%
ROIC/WACCN/A
Cap/Depr(3y)106.33%
Cap/Depr(5y)205.47%
Cap/Sales(3y)3.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.8%
EPS Next Y-131.58%
EPS Next 2Y70.14%
EPS Next 3Y146.58%
EPS Next 5YN/A
Revenue 1Y (TTM)-94.09%
Revenue growth 3Y-33.42%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-52.86%
Revenue Next 2Y33.1%
Revenue Next 3Y88.24%
Revenue Next 5YN/A
EBIT growth 1Y-6.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-114.29%
EBIT Next 3Y152.58%
EBIT Next 5YN/A
FCF growth 1Y40.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.71%
OCF growth 3YN/A
OCF growth 5YN/A

AELIS FARMA SAS / AELIS.PA Fundamental Analysis FAQ

What is the fundamental rating for AELIS stock?

ChartMill assigns a fundamental rating of 2 / 10 to AELIS.PA.


Can you provide the valuation status for AELIS FARMA SAS?

ChartMill assigns a valuation rating of 3 / 10 to AELIS FARMA SAS (AELIS.PA). This can be considered as Overvalued.


Can you provide the profitability details for AELIS FARMA SAS?

AELIS FARMA SAS (AELIS.PA) has a profitability rating of 0 / 10.


Can you provide the financial health for AELIS stock?

The financial health rating of AELIS FARMA SAS (AELIS.PA) is 3 / 10.